Primary Aldosteronism

A call to action for screening and optimization of laboratory screening methods

Tuesday, July 26
12:45 – 1:45 p.m.
Exhibit Hall Theater 3
Supported by DiaSorin


Primary aldosteronism (PA) is a significant public health condition recognized as a major subset within the hypertensive population. Unlike the majority of hypertension, its singular pathophysiologic basis enables precise and highly effective treatment options. Diagnostic challenges that plague providers include an under-recognition of PA prevalence and concern regarding testing conditions surrounding aldosterone and renin assessments.


After attending this session, participants will be able to:

  • Understand the clinical impact of primary aldosteronism.
  • Recognize the need for increased screening in at-risk populations.
  • Gain insight into best practices for laboratories converting from plasma renin activity to direct renin concentration.


Andrea Diebel
Product Manager


Jonathan S. Williams, MD, MMSc
Associate Professor of Medicine - Harvard Medical School
Director, Cardiovascular Endocrine Human Genetics
Research Program - Brigham and Women’s Hospital

Alison Woodworth, PhD, DABCC, FAACC
Professor, Clinical Title Series
Medical Director, Clinical Chemistry and Point of Care Testing